COGT · XBRL financial data

Cogent Biosciences financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (COGT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	26	56	122	174	233	270
General and administrative	17	20	26	34	43	64
Operating income (loss)	(82)	(76)	(148)	(208)	(276)	(333)
Interest income	0	0	4	13	18	15
Interest expense	—	—	—	—	—	3
Other income (expense)	—	—	2	1	2	(0)
Income tax expense (benefit)	—	—	—	—	—	0
Net income (loss)	(75)	(72)	(140)	(192)	(256)	(329)
Earnings per share, basic USD per share	—	(1.87)	(2.39)	(2.42)	(1.94)	(2.16)
Earnings per share, diluted USD per share	—	(1.87)	(2.39)	(2.42)	(1.94)	(2.16)
Weighted average shares, basic millions of shares	—	39	59	80	104	129
Weighted average shares, diluted millions of shares	—	39	59	80	104	129

Fiscal years (COGT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	242	220	140	53	98	312
Marketable securities	—	0	119	212	189	589
Marketable securities, non-current	—	—	0	7	—	—
Prepaid and other current assets	3	3	4	5	9	10
Total current assets	245	223	265	271	296	910
Property and equipment, net	0	2	8	8	6	5
Right-of-use asset	5	3	23	22	20	18
Total assets	251	232	301	313	328	938
Accounts payable	1	3	6	11	12	10
Total current liabilities	13	17	27	38	56	64
Long-term debt	—	—	—	—	0	—
Lease liability, non-current	3	1	18	17	16	14
Total liabilities	16	18	45	56	72	301
Accumulated deficit	(199)	(271)	(411)	(604)	(859)	(1,188)
Total stockholders' equity	235	214	256	258	256	636
Total liabilities and equity	251	232	301	313	328	938
Common shares outstanding (cover page) millions of shares	37	46	70	104	114	162

Fiscal years (COGT's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(75)	(72)	(140)	(192)	(256)	(329)
Stock-based compensation	6	12	18	31	40	46
Net cash from operating activities	(36)	(59)	(119)	(154)	(208)	(264)
Purchases of property and equipment	—	2	7	3	1	2
Net cash from investing activities	8	(2)	(125)	(98)	38	(400)
Proceeds from issuing common stock	25	0	0	162	0	—
Proceeds from long-term debt	—	—	—	0	0	49
Net cash from financing activities	232	38	164	164	214	878
Net change in cash	205	(23)	(80)	(88)	45	214

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Cogent Biosciences	181	not reported	(77)*	173.5M	10.3 quarters	Q2 FY26 10-QJun 30, 2026
uniQure	98	5.2	(48)*	70.1M	2.6 quarters	Q3 FY26 10-QSep 30, 2026
Phibro Animal Health	76	387	26	not reported	—	Q1 FY27 10-QSep 30, 2026
Pacira BioSciences	206	192	57*	39.9M	—	Q2 FY26 10-QJun 30, 2026
Syndax Pharmaceuticals	136	83	(27)*	not reported	11.9 quarters	Q3 FY26 10-QSep 30, 2026
Nurix Therapeutics	720	673	616*	109.2M	—	Q3 FY26 10-QAug 31, 2026
Niagen Bioscience	70	27	not reported	79.2M	—	Q3 FY26 10-QSep 30, 2026
Immunome	218	0	(62)*	113.6M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Anavex Life Sciences	118	not reported	(9.1)*	92.7M	13.0 quarters	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.